Cambridge Angels

"It’s an entirely new engineered GaN material platform to build semiconductor devices on. It offers performance improvements that are suitable for mass production, scalable in wafer size – and crucial for the next generation of microdisplay devices such as AR glasses."

"The idea for Scale XP came when – particularly once the pandemic hit – we identified a huge demand among the small business community for an easy-to-use tool that can support them on their growth journey. We wanted to give them an easier way to oversee their business performance, holistically, so that they can thrive. I’m delighted by the huge interest and support from the VC community and female founder networks like Angel Academe to help us realise this mission. It’s fantastic to have Alex on the Advisory Board to help us scale the business quickly."

"Our investors recognise the potential of our AI-powered antibody drug discovery platform to provide a breakthrough in the industry. With our technology, it will be possible to develop drugs for difficult targets and ultimately reduce drug discovery timescales from years to weeks. In addition to platform development, the funding will enable us to invest in facilities and recruitment; we are grateful to our investors and Innovate UK for their continued support."

"This latest round of investment is a great recognition of our success to date, with new and existing investors confirming the strength of our technology. Since 2016, CGD has grown significantly and we are thrilled to be in a position to deliver several products to market, following decades of industry-leading research in reliability of power devices. This investment will allow us to supplement our experienced team with additional experts and expand our markets globally, creating more sustainable electronics worldwide."